PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - White, William B.
TI  - Benefits of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Cardiovascular Risk
DP  - 2013 Dec 01
TA  - MD Conference Express
PG  - 27--28
VI  - 13
IP  - 17
4099  - http://mdc.sagepub.com/content/13/17/27.short
4100  - http://mdc.sagepub.com/content/13/17/27.full
AB  - Many studies have shown that improved glucose control in patients with diabetes reduces microvascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glucose control and were thought to reduce the risk of cardiovascular events and all-cause mortality in patients with type 2 diabetes [Monami M et al. Diabetes Obes Metab 2013]. This article discusses the Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care trial [EXAMINE; NCT00968708] and Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus [SAVOR]-TIMI 53 trial [NCT01107886] trials.